Sunday, June 26, 2022

A Guide To The Risks Of Investing In Rubius Therapeutics Inc. (RUBY)

Rubius Therapeutics Inc.’s filing revealed that its Director Epstein David R acquired Company’s shares for reported $43329.0 on Apr 21. In the deal valued at $1.44 per share,30,000 shares were bought. As a result of this transaction, Epstein David R now holds 4,720,012 shares worth roughly $ 4.3 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Then, CAGNONI PABLO J sold 6,730 shares, generating $44,236 in total proceeds. Upon selling the shares at $6.57, the CEO and President now owns 35,520 shares.

Before that, Turka Laurence A. sold 2,517 shares. Rubius Therapeutics Inc. shares valued at $16,544 were divested by the Chief Scientific Officer at a price of $6.57 per share. As a result of the transaction, Turka Laurence A. now holds 4,921 shares, worth roughly $4478.110000000001.

PT values the company’s stock at a premium of 95.86 to its Tuesday closing price. A number of analysts have revised their coverage, including SVB Leerink’s analysts, who decreased its forecast for the stock in mid March from “an Outperform” to “a Mkt perform”. Morgan Stanley also remained covering RUBY and has decreased its forecast on March 13, 2020 with a “an Equal-weight” recommendation from previously “an Overweight” rating. JP Morgan revised its rating on January 31, 2020. It rated RUBY as “a Neutral” which previously was an “an Overweight”.

Price Performance Review of RUBY

On Tuesday, Rubius Therapeutics Inc. [NASDAQ:RUBY] saw its stock fall -1.98% to $0.91. On the same session, the stock had its day’s lowest price of $0.9005, but rose to a high of $1.08. Over the last five days, the stock has gained 2.38%. Rubius Therapeutics Inc. shares have fallen nearly -90.56% since the year began. Nevertheless, the stocks have fallen -96.34% over the past one year. While a 52-week high of $26.33 was reached on 01/04/22, a 52-week low of $0.75 was recorded on 06/16/22. SMA at 50 days reached $1.3740, while 200 days put it at $8.7738. A total of 0.97 million shares were traded, compared to the trading of 0.98 million shares in the previous session.

Levels Of Support And Resistance For RUBY Stock

The 24-hour chart illustrates a support level at 0.8495, which if violated will result in even more drops to 0.7853. On the upside, there is a resistance level at 1.0290. A further resistance level may holdings at 1.1443. The Relative Strength Index (RSI) on the 14-day chart is 39.25, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0986, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 80.02%. Stochastics %K at 21.48% indicates the stock is a holding.

Rubius Therapeutics Inc. [RUBY] – Who Are The Largest Shareholders?

In filings from Fidelity Management & Research Co, it is revealed that the company now owns 13,527,993 shares, or roughly 15.00% of the outstanding RUBY shares. In other words, the investor’s shares have risen by 48,127 from its previous 13-F filing of 13479866.0. Additionally, Baillie Gifford & Co. decreased -0.47% of its stake after which the total value it holdings stand at $5,398,218, while Invus Public Equities Advisors LL reduced 0.00% of its stake to hold $4.07 million in the firm. Over the last quarter, BlackRock Fund Advisors purchased 10,529 shares of Rubius Therapeutics Inc., while Victory Capital Management, Inc. bought 489,248 shares. At present, Capital Research & Management Co is holding 2,751,000 shares valued at $3.03 million. The Vanguard Group, Inc. owned 2,216,845 shares of the company at the time of its most recent 13F filing, worth $2.44 million.

According to FactSet, Rubius Therapeutics Inc.’s share price will average $8.40 in the next year, based on opinions of analysts polled by the firm. This is up nearly 222.58 percent from its previous closing price of $0.93. Analysts expect Rubius Therapeutics Inc. stock to reach the higher price of $20.00, while the lowest price estimate is $2.00. However, 5 analysts have rated RUBY stock as an Overweight in their predictions for 2022. The most recent change occurred on September 10, 2019 when Robert W. Baird began covering the stock and recommended ‘”an Underperform”‘ rating.

Latest news

Related news


Please enter your comment!
Please enter your name here




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam